| Biomarker ID | 1731 |
| PMID | 30286759 |
| Year | 2018 |
| Biomarker | hsaâ€mirâ€891a; hsaâ€mirâ€892a; hsaâ€mirâ€1224; hsaâ€mirâ€93; hsaâ€mirâ€23c; hsaâ€mirâ€1251; hsaâ€mirâ€204; hsaâ€mirâ€323b; hsaâ€mirâ€200c; hsaâ€mirâ€96; |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated after surgery (Before Surgery: 31.05 ± 21.01; After Surgery: 23.14 ± 11.1) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Normal Adjacent |
| Type of Biomarker | Diagnostic |
| Cohort | A total of 551 samples were collected, comprising 499 primary prostate cancer samples and 52 normal solid tissue samples. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | RNASeqV2 and Illumina HiSeq 2000 miRNA sequencing |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |